SCHEMBL6296289

SCHEMBL6296289

COC(=O)c1ccc(SC(=O)N(C)C)c(C(C)(C)C)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.43
ALDH1A1 P00352 7/20 0.43
MAPT P10636 6/20 0.43
HPGD P15428 5/20 0.43
LMNA P02545 4/20 0.43
HSD17B10 Q99714 3/20 0.43
ALOX15 P16050 2/20 0.43
MEN1 O00255 1/20 0.43
TP53 P04637 1/20 0.43
ALOX12 P18054 1/20 0.43
HTT P42858 1/20 0.43
KMT2A Q03164 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CA12 O43570 2/20 0.41
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
CA7 P43166 2/20 0.41
CA9 Q16790 2/20 0.41
CA14 Q9ULX7 2/20 0.41
XDH P47989 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4211346 0.81 MAPT (0.46) KDM4EALDH1A1MAPTHPGDLMNA
SCHEMBL8095754 0.81 HPGD (0.46) KDM4EALDH1A1MAPTHPGDLMNA
SCHEMBL8087032 0.80 KDM4E (0.57) KDM4EALDH1A1MAPTHPGDLMNA
SCHEMBL8010796 0.80 MAPT (0.33) KDM4EALDH1A1MAPTHPGDLMNA
SCHEMBL13495880 0.78 ALDH1A1 (0.50) KDM4EALDH1A1MAPTHPGDLMNA
SCHEMBL3549964 0.77 MAPT (0.51) KDM4EALDH1A1MAPTHPGDLMNA
SCHEMBL30037411 0.77 MAPT (0.51) KDM4EALDH1A1MAPTHPGDLMNA
SCHEMBL8101046 0.76 HPGD (0.58) ALDH1A1MAPTHPGDLMNAMEN1
SCHEMBL13440125 0.75 NOTUM (0.56) KDM4EALDH1A1MAPTHPGDLMNA
SCHEMBL6747661 0.73 VCAM1 (0.50) KDM4EALDH1A1MAPTHPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050075390-A1 HIV protease inhibitors AGOURON PHARMACEUTICALS, INC. 2005-04-07 US disclosed
US-6852711-B2 Novel dihydropyrones with tethered heterocycles having improved pharmacologic properties which potently inhibit the HIV aspartyl protease blocking HIV infectivity. The dihydropyrones are useful in the development of therapies for AGOURON PHARMACEUTICALS, INC. (US) 2005-02-08 US disclosed
US-20040106606-A1 HIV protease inhibitors BOYER FREDERICK EARL (US) 2004-06-03 US disclosed
US-6528510-B1 Dihydropyrones with tethered heterocycles; 3-(2-tert-Butyl-4-hydroxymethyl-5-methyl-phenylsulfanyl)-4-hydroxy-6 -isopropyl-6-(2-pyridin-4-yl-ethyl)-5,6-dihydro-pyran - 2-one; WARNER-LAMBERT COMPANY 2003-03-04 US disclosed
EP-1112269-A2 HIV PROTEASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-07-04 EP disclosed
WO-2000015634-A2 HIV PROTEASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2000-03-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106606-A1 HIV protease inhibitors DNPEP, PREP, PEPD KDM4E 1555/4885ALDH1A1 1219/4885MAPT 1327/4885
US-20050075390-A1 HIV protease inhibitors DNPEP, PREP, PEPD KDM4E 1634/4885ALDH1A1 1309/4885MAPT 1198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.